A study to know the effect of low molecular weight heparin in treatment of acute pancreatitis.

Low molecular weight heparin in treatment of moderately severe and severe acute pancreatitis; A randomized control trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/032665

Enrollment

140

Registered

2021-04-08

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K859- Acute pancreatitis, unspecified Health Condition 2: K852- Alcohol induced acute pancreatitis Health Condition 3: K851- Biliary acute pancreatitis Health Condition 4: K853- Drug induced acute pancreatitis Health Condition 5: K850- Idiopathic acute pancreatitis Health Condition 6: K858- Other acute pancreatitis

Interventions

Intervention1: Low molecular weight heparin (Enoxaparin) with conventional treatment: Low molecular weight heparin in the form of enoxaparin is given at the dose of 1mg/kg body weight 12 hourly along

Eligibility

Inclusion criteria

Inclusion criteria: Patients of moderately severe or severe acute pancreatitis. Admitted within 24hours of onset of symptoms. willing to participate

Exclusion criteria

Exclusion criteria: Chronic pancreatitis. Traumatic pancreatitis. Hypersensitivity to low molecular weight heparin, heparin, pork products, benzyl alcohol or other ingredients of enoxaparin preparation or radio contrast agent. Any contraindication for low molecular weight heparin. Pregnancy and lactation. Charlson Comorbidity Index 5 or more

Design outcomes

Primary

Measure	Time frame
Pancreatic NecrosisTimepoint: Baseline and at the end of one week of treatment	—

Secondary

Measure	Time frame
Clinical wellbeing(time taken to tolerate oral feeds, time of relief from abdominal symptoms and signs, mean duration of hospital stay)Timepoint: During the period of current episode of acute pancreatitis;Local and systemic complicationsTimepoint: During the period of current episode of acute pancreatitis;MortalityTimepoint: During the period of current episode of acute pancreatitis;Need for surgical, endoscopic or minimal invasive procedureTimepoint: During the period of current episode of acute pancreatitis	—

Measure

Time frame

Clinical wellbeing(time taken to tolerate oral feeds, time of relief from abdominal symptoms and signs, mean duration of hospital stay)Timepoint: During the period of current episode of acute pancreatitis;Local and systemic complicationsTimepoint: During the period of current episode of acute pancreatitis;MortalityTimepoint: During the period of current episode of acute pancreatitis;Need for surgical, endoscopic or minimal invasive procedureTimepoint: During the period of current episode of acute pancreatitis

—

Countries

India

Contacts

Public ContactDr Basavaraj

SMS Medical College and Attached Hospitals, Jaipur

basavaraj_kindle@yahoo.com9449468782

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026